Please select your location and reference genome:
Congenica and IAB Agree to Distribution Deal in Central Europe

Congenica and IAB Agree to Distribution Deal in Central Europe

1/27/2022    |    0 min read

Congenica and the Institute of Applied Biotechnologies Agree to Distribution Deal in Central Europe


Cambridge, United Kingdom - 27th January 2022  Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a strategic partnership with the Institute of Applied Biotechnologies (IAB) as a distributor for Czech Republic, Slovakia, Hungary and Poland.


IAB will distribute Congenica’s CE Marked IVD clinical decision support software platform across Europe to both public and private healthcare and research partners. Delivering expertise in Next-Generation Sequencing (NGS) and informatic solutions, IAB provides complete NGS services using the most up-to-date and state-of-the-art technologies.


IAB understands that providing complete genomic services requires sophisticated informatics analytical procedures able to process large amounts of genomic data for accurate and consistent interpretation of NGS results. Congenica’s leading technology platform enables the rapid analysis and interpretation of complex genomic data, allowing the delivery of personalised medicine at scale.


Willem Haagmans, VP Sales EMEA at Congenica, said: We’re delighted to be working with IAB to help strengthen our presence in Central Europe as part of our fast-moving global expansion plans. The team offer great knowledge and an excellent network and are well positioned to help rollout our leading genomic analysis platform in this important region.


Petr Kvapil, CEO at IAB, said: We searched for a user-friendly and reliable NGS data analysis and interpretation suite that could be used daily in diagnostic labs without the need for an army of trained bioinformaticians. Genetic diagnostics based on exome/genome sequencing is evolving rapidly, but a bottleneck is the effective and rapid analysis of the enormous datasets produced by NGS. Congenica is the perfect solution for these challenges, and we are very excited about the future product developments they have planned. We’re very pleased to be offering Congenica’s clinical interpretation and management software - it’s the cherry on the top of the cake in our NGS portfolio.”




Contact details for editorial enquiries:
Becky Lamont, Marketing Communications Manager at Congenica
Email: becky.lamont@congenica.com
Contact IAB: iabio@iabio.eu

About Congenica

Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers to provide life-changing answers that improve wellbeing and disease management.


Congenica’s world-leading software enables rapid genomic data analysis at scale, performing 20x faster than industry averages and providing a 30% higher analytical yield, reducing genomic interpretation costs by up to 95%.


Born out of pioneering research from the WellcomeSanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.


About Institute of Applied Biotechnologies

Beside other technologies like optical genome mapping, IAB focuses on the whole Illumina NGS workflow. Starting with the most advanced technologies for nucleic acids purification, through various technologies for library preparation and targeted enrichment or the best sequencing practise on Illumina instruments, ending with the most advanced informatic approaches to analyse and interpret the NGS data.